Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Haolin Ni who wrote (1410)	11/13/1998 8:33:00 AM
From: celeryroot.com	Read Replies (2) \| Respond to of 2135

wish he'd ask them abt their connection to DH Blair

To: Haolin Ni who wrote (1410)	11/13/1998 8:45:00 AM
From: Mr. Miller	Read Replies (1) \| Respond to of 2135

He said that he knows nothing about a 10-day review by the NIH. Either way, you are taking it out of context. When I worked for NIEHS, we had collaborations with pharmaceuticals all the time. They visit often to learn the technique and understand the models we use. Also, it is unprofessional to draw attention to these other entities who have substantiated the results. The media would be all over them. Abstracts will be presented in April, and papers are in press to be published. Even as a staunch bull here, I say the writing is on the wall. He will have hell to pay if the papers aren't out or abstracts aren't presented in April. I doubt he would want that kind flack. We are talking about a cure or solid treatment of cancer, and you are hoping that this company fails? What kind of person are you Haolin? You do not deserve my responses if all you have to offer are these no basis blips. I think the story looks better than before, and with papers coming to substantiate ENMD data, I think the WSJ needs to do a better study of the situation, because I will have no love loss for them when the journals come to refute their sorry news coverage. Miller